1. Home
  2. EMAT vs URGN Comparison

EMAT vs URGN Comparison

Compare EMAT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolution Metals & Technologies Corp. Common Stock

EMAT

Evolution Metals & Technologies Corp. Common Stock

N/A

Current Price

$2.16

Market Cap

2.6B

Sector

N/A

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$40.70

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EMAT
URGN
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
EMAT
URGN
Price
$2.16
$40.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$8.25
★ $60.00
AVG Volume (30 Days)
★ 1.1M
579.2K
Earning Date
08-17-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,128,000.00
Revenue This Year
N/A
$193.48
Revenue Next Year
$1,102.50
$68.06
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.15
$15.86
52 Week High
$17.50
$50.81

Technical Indicators

Market Signals
Indicator
EMAT
URGN
Relative Strength Index (RSI) 36.30 40.98
Support Level $2.15 $40.94
Resistance Level $4.73 $44.63
Average True Range (ATR) 0.49 1.63
MACD -0.09 -0.23
Stochastic Oscillator 1.13 23.37

Price Performance

Historical Comparison
EMAT
URGN

About EMAT Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp is a critical materials and technology company. The company is focused on developing a secure, dependable, and self-sustaining U.S.-aligned supply chain for critical minerals and materials (CMM), and rare earth elements (REEs). The company is also engaged in recycling end-of-life materials through urban mining to help strengthen domestic resource independence and long-term supply stability.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: